Hepatitis Acute Articles & Analysis
2 news found
– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 20, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), ...
However, intravenous treatment with the necessary dose of tigecycline (200 mg/day) has severe side effects, including excessive vomiting, hepatic dysfunction and acute pancreatitis. In order to overcome this obstacle, Radboudumc also researched inhaled administration of tigecycline. ...